Industry Symposia


MONDAY 20TH AUGUST

Ipsen Breakfast Symposium - Limited places available

Date: Monday 20th August 

Time: 7.00am to 8.15am (breakfast served from 6:45am)

Title: Pituitary Tumour Genetics - where are we in 2018

Content: 
During this symposium the Australia and New Zealand Pituitary Alliance (ANZPA) will be launched and the objectives and activities of ANZPA will be discussed.  A lecture on pituitary tumour genetics will also be delivered. The last few years has seen an increasing repertoire of genes implicated in pituitary tumour predisposition. This lecture outlines which genes are implicated, associated phenotypes and role of genetic testing. The lecture will be supported by case study presentation and discussion.

Presenter: Dr Ann McCormack

Chairs: A/Prof Rory Clifton-Bligh and Dr Christopher Yates

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byIpsen2  

 

Eisai Breakfast Symposium

Date: Monday 20th August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: What's new in 2018: A practical guide to prescribing Tyrosine Kinase Inhibitors (TKIs)

Summary/Synopsis: - An Australian panel of experts in the treatment of RAI-R DTC discuss recent publications relating to the use of Tyrosine Kinase Inhibitors (TKIs) and practical considerations for treating RAI-R DTC with systemic therapy in the Australian context.

Presenters: Liza Nery, Prof Bruce Robinson & Prof Duncan Topliss

Chair: Prof Bruce Robinson

Topic 1:
Defining a radioiodine refractory (RAI-RR) Differentiated Thyroid Cancer (DTC) patient and recognizing treatment eligibility/appropriateness for referral in Australia 
Topic 2:
Determining when Tyrosine Kinase Inhibitor (TKI) therapy may be appropriate for RAI-R DTC patients (triggers for initiation of treatment or referral) 
Topic 3:
Proactive management of patients to ensure optimal long-term benefit from treatment
Topic 4:
Practical considerations when treating with TKIs including utilisation of nurse support and MDT approach.

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byEisailogo4

 

 

TUESDAY 21ST AUGUST

 

Pfizer Endocrine Care Breakfast Symposium

Date: Tuesday 21st August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: 21 years after the first injection of Pegvisomant to humans

Content: Prof AJ van der Lely will share his extensive experience in treating patients with acromegaly including diagnosis, treatment and 21 years experience using Pegvisomant.     
Topic 1: 
Treatment paradigm in acromegaly 
Prof Aart Jan van der Lely

Topic 2: 
Real world experience with  Pegvisomant
Prof Aart Jan van der Lely

Chair: Prof David Torpy 

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byPfizer Endocrine Care1

 

Novo Nordisk Pharmaceuticals Breakfast Symposium 

Date: Tuesday 21st August 

Time: 7.00am to 8.00am (breakfast served from 6:45am)

Title: New Directions in Diabetes Management – Introducing Ryzodeg® 70/30

Content: 

During this symposium an expert panel of speakers will discuss Ryzodeg® 70/30 (insulin degludec / insulin aspart) mode of action (MOA) and provide a balanced overview of the Ryzodeg® 70/30 clinical trial programme as well as discuss the clinical implications this new insulin will have on the management of diabetes in Australia.

    
Topic 1: 
Ryzodeg® 70/30 Mode of Action

Topic 2: 
Ryzodeg® 70/30 Clinical Data Overview  

Presenters: Prof Richard MacIsaac & Prof Tim Davis

Chair: Prof Roger Chen 

Prof Richard MacIsaac
Richard MacIsaac is professor and director of Endocrinology and Diabetes at St Vincent’s Hospital Melbourne and the University of Melbourne.  Prior to taking up his current position he was head of diabetes at Austin Health, Melbourne.  His main research interest is diabetes and its complications, especially those related to cardiovascular and kidney disease.  He has published over 200 research articles.   He graduated from the University of Melbourne’s Medical School in 1995 and was awarded his fellowship with the Royal Australasian College of Physicians in 2002.  Currently specific research interests are inpatient glycaemic control, defining the albuminuria and glomerular filtration rate relationship in diabetes, investigating new biomarkers for renal and vascular disease in diabetes and studying renal function in indigenous Australians. He also has an interest in the application of new medicines and technologies to improve glycaemic control and outcomes in people with diabetes.

Prof Tim Davis
Professor Timothy Davis is an endocrinologist, general physician and tropical medicine specialist at Fremantle Hospital, and Professor of Medicine at the University of Western Australia. He had research interests in diabetes since 1978 and in tropical medicine since 1987, and is still active in both areas. Professor Davis is principal investigator of the Fremantle Diabetes Study, a large-scale prospective study of diabetes in a community-based cohort. He is also a Busselton Health Study investigator and an associate investigator on the United Kingdom Prospective Diabetes Study. His tropical/infectious diseases research group is involved in collaborative studies of malaria and bacterial infections in children and pregnant women in Papua New Guinea. Professor Davis is author or co-author of more than 400 original papers, the majority on diabetes, endocrinology, malaria and other tropical diseases. Professor Davis is a member and past Vice President of the Australian Diabetes Society and was the Society’s 2014 Kellion Lecturer in recognition of his outstanding contribution to diabetes research and clinical care in Australia. He is a Co-Deputy Chair of the Australian Government Medical Services Advisory Committee, and a member of the Australian Government’s Commonwealth Science Council.

This Breakfast Session is complimentary, however you must sign up for it via your conference registration here.

This session is supported and organised byNovoN 2c CMYK Coated

  


Our Sponsors